{"denoms":[{"counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"94"}],"units":"Participants"}],"groups":[{"description":"Adult participants with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) were received brentuximab vedotin (genetic recombination) 1.8 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every three weeks (up to 12 months). The dose should be reduced appropriately depend on the participant's condition. Participants received interventions as part of routine medical care.","id":"BG000","title":"Adult Participants With PTCL-NOS"},{"description":"Adult participants with angioimmunoblastic T-cell lymphoma (AITL) were received brentuximab vedotin (genetic recombination) 1.8 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every three weeks (up to 12 months). The dose should be reduced appropriately depend on the participant's condition. Participants received interventions as part of routine medical care.","id":"BG001","title":"Adult Participants With AITL"},{"description":"Adult participants with adult T-cell leukemia/lymphoma (ATLL) were received brentuximab vedotin (genetic recombination) 1.8 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every three weeks (up to 12 months). The dose should be reduced appropriately depend on the participant's condition. Participants received interventions as part of routine medical care.","id":"BG002","title":"Adult Participants With ATLL"},{"description":"Adult participants with the other PTCL (peripheral T-cell lymphoma \\[PTCL\\] subtypes other than anaplastic large-cell lymphoma \\[ALCL\\] \\[not surveyed\\], PTCL-NOS, AITL, and ATLL) were received brentuximab vedotin (genetic recombination) 1.8 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every three weeks (up to 12 months). The dose should be reduced appropriately depend on the participant's condition. Participants received interventions as part of routine medical care.","id":"BG003","title":"Adult Participants With Other PTCL"},{"description":"Pediatric participants with peripheral T-cell lymphoma (PTCL) were received brentuximab vedotin (genetic recombination) 1.8 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every three weeks (up to 12 months). The dose should be reduced appropriately depend on the participant's condition. Participants received interventions as part of routine medical care.","id":"BG004","title":"Pediatric Participants With PTCL"},{"description":"Pediatric participants with Hodgkin lymphoma (HL) were received brentuximab vedotin (genetic recombination) 1.8 milligrams per kilograms (mg/kg) (body weight), intravenous infusion, once every three weeks (up to 12 months). The dose should be reduced appropriately depend on the participant's condition. Participants received interventions as part of routine medical care.","id":"BG005","title":"Pediatric Participants With HL"},{"description":"Total of all reporting groups","id":"BG006","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.01","value":"69.9"},{"groupId":"BG001","spread":"9.23","value":"72.6"},{"groupId":"BG002","spread":"12.82","value":"68.0"},{"groupId":"BG003","spread":"23.52","value":"49.2"},{"groupId":"BG004","spread":"3.69","value":"12.3"},{"groupId":"BG005","spread":"4.24","value":"12.0"},{"groupId":"BG006","spread":"20.47","value":"64.4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"94"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"48"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"46"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"94"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG006","value":"0"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Race and Ethnicity were not collected from any participant.","title":"Race and Ethnicity Not Collected","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"94"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"94"}],"units":"Participants"}],"title":"Japan"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"42.96","value":"35.7"},{"groupId":"BG001","spread":"36.30","value":"31.0"},{"groupId":"BG002","spread":"64.90","value":"37.2"},{"groupId":"BG003","spread":"8.57","value":"5.7"},{"groupId":"BG004","spread":"2.94","value":"5.0"},{"groupId":"BG005","spread":"12.69","value":"18.3"},{"groupId":"BG006","spread":"42.01","value":"30.2"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"94"}],"units":"Participants"}]}],"description":"Mean duration between the first diagnosis of relapsed or refractory CD30 positive peripheral T-cell lymphoma (PTCL) or Hodgkin lymphoma (HL: pediatric participants only) and the first dose was reported.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Duration of Diagnosis of PTCL or HL","unitOfMeasure":"Months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"35"}],"title":"Scale = 0"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"41"}],"title":"Scale = 1"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"11"}],"title":"Scale = 2"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"5"}],"title":"Scale = 3"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"}],"title":"Scale = 4"}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"94"}],"units":"Participants"}]}],"description":"Eastern Cooperative Oncology Group performance status assess participant's performance status on 5 point scale: 0=Fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (greater than \\[\\>\\] 50 percent \\[%\\] of waking hours), capable of all self-care, unable to carry out any work activities; 3=capable of only limited selfcare, confined to bed/chair \\>50% of waking hours; 4=completely disabled, cannot carry on any self-care, totally confined to bed/chair; 5=dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"15"}],"title":"Outpatient"},{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"79"}],"title":"Inpatient"}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"94"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Healthcare Category","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"30"}],"title":"Had No Medical Complications"},{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"64"}],"title":"Had Medical Complications"}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"94"}],"units":"Participants"}]}],"description":"Complications defined as a disease or a health condition for each participant at the start of study. Complications were classified as congenital anomalies, endocrine disorders, hematologic disorders, psychiatric and nervous system disorders, cardiovascular disorders, respiratory disorders, gastrointestinal (GI) disorders, renal disease and other complications. Other complications included all complications except for those mentioned above.","paramType":"COUNT_OF_PARTICIPANTS","title":"Medical Complications","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"11"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"61"}],"title":"Had No Medical History"},{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"32"}],"title":"Had Medical History"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"}],"title":"Unknown"}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"94"}],"units":"Participants"}]}],"description":"Medical history defined as a disease or a health condition for each participant before start of the study. Medical history was classified as congenital anomalies, hematologic disorders, psychiatric and nervous system disorders, cardiovascular disorders, respiratory disorders, GI disorders, hepatic and biliary disorders, renal disease and other medical history. Other medical history included all medical history except for those mentioned above. Unknown: Data could not be collected.","paramType":"COUNT_OF_PARTICIPANTS","title":"Medical History","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"44"}],"title":"Never Smoked"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"5"}],"title":"Current Smoker"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"29"}],"title":"Ex-Smoker"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"16"}],"title":"Unknown"}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"94"}],"units":"Participants"}]}],"description":"Unknown: Data could not be collected.","paramType":"COUNT_OF_PARTICIPANTS","title":"Smoking Classification","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.031","value":"57.65"},{"groupId":"BG001","spread":"12.328","value":"54.01"},{"groupId":"BG002","spread":"10.082","value":"52.14"},{"groupId":"BG003","spread":"12.517","value":"56.77"},{"groupId":"BG004","spread":"7.677","value":"41.75"},{"groupId":"BG005","spread":"21.386","value":"47.00"},{"groupId":"BG006","spread":"12.167","value":"54.29"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"94"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Weight","unitOfMeasure":"Kilograms (kg)"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"3.536","value":"22.20"},{"groupId":"BG001","spread":"3.764","value":"21.85"},{"groupId":"BG002","spread":"4.059","value":"20.86"},{"groupId":"BG003","spread":"5.033","value":"22.43"},{"groupId":"BG004","spread":"2.981","value":"18.08"},{"groupId":"BG005","spread":"5.239","value":"20.73"},{"groupId":"BG006","spread":"3.858","value":"21.65"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"94"}],"units":"Participants"}]}],"description":"Body Mass Index = weight (kg)/\\[height (m)\\^2\\]","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"BMI","unitOfMeasure":"Kilogram (kg)/meter (m)^2"}],"populationDescription":"Safety Analysis Set, The safety analysis set was defined as all participants who completed the survey."}